Third‐Trimester Cardiovascular Function and Risk of Hypertensive Disorders of Pregnancy
Journal of the American Heart Association · 2024
DOI: 10.1161/jaha.123.032673 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Frederikke Lihme und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology Research Statens Serum Institut Copenhagen Denmark. Hauptthemen laut MEDLINE: Pregnancy Trimester, Third, Hypertension, Pregnancy-Induced, Pre-Eclampsia, Vascular Resistance. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Whether cardiovascular dysfunction is associated with preeclampsia in women without fetal growth restriction (FGR) is unclear. Our objective was to investigate associations between third‐trimester cardiac output (CO) and systemic vascular resistance and risk of hypertensive disorders of pregnancy in women with and without FGR. Methods and Results A case–cohort study in 906 pregnant women in Denmark with repeated third‐trimester cardiac function assessments was performed using the Ultrasound Cardiac Output Monitor 1A. Using Cox regression, we compared rates of hypertensive disorders of pregnancy in women with low, normal, and high CO and normal and high systemic vascular resistance, by FGR status and gestational age, and evaluated associations between a third‐trimester drop in CO or increase in systemic vascular resistance and preeclampsia risk in women without FGR. The analysis included 249 women with preeclampsia (42 with FGR) and 119 women with gestational hypertension. Low CO was strongly associated with preeclampsia at 75th percentile and preeclampsia in women without FGR (odds ratio, 1.91 [95% CI, 0.84–4.36]). High systemic vascular resistance was strongly associated with increased rates of all forms of hypertensive disorders of pregnancy.
Conclusions
Low CO is associated with preeclampsia risk in women with and without FGR, particularly before 37 weeks. Repeated measurements of third‐trimester cardiovascular function might identify women without FGR for monitoring for preeclampsia, but this result needs to be confirmed in other studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology Research Statens Serum Institut Copenhagen Denmark.
- Department of Obstetrics Copenhagen University Hospital Herlev Denmark.
- Department of Gynaecology and Obstetrics Rigshospitalet Copenhagen Denmark.
- Department of Gynaecology and Obstetrics Hvidovre Hospital Copenhagen Denmark.
- Danish Cancer Institute Copenhagen Denmark.
- Department of Clinical Medicine University of Copenhagen Copenhagen Denmark.
ORCID-Profile: Frederikke Lihme, Saima Basit, Lisa G Persson, Jacob A Lykke, Kasper Pihl, Mads Melbye, Jan Wohlfahrt, Heather A Boyd
Förderung
- NHLBI NIH HHS
Zitieren
APA
Lihme, F., Basit, S., Persson, L. G., Larsen, M. O., Lauridsen, K. H., Lykke, J. A., Andersen, A. S., Thorsen-Meyer, A., Pihl, K., Melbye, M., Wohlfahrt, J., & Boyd, H. A. (2024). Third‐Trimester Cardiovascular Function and Risk of Hypertensive Disorders of Pregnancy. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.032673
Vancouver
Lihme F, Basit S, Persson LG, Larsen MO, Lauridsen KH, Lykke JA, et al. Third‐Trimester Cardiovascular Function and Risk of Hypertensive Disorders of Pregnancy. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.032673
BibTeX
@article{Lihme2024,
author = {Lihme, Frederikke and Basit, Saima and Persson, Lisa G and Larsen, Maria O and Lauridsen, Karin H and Lykke, Jacob A and Andersen, Anita S and Thorsen-Meyer, Annette and Pihl, Kasper and Melbye, Mads and Wohlfahrt, Jan and Boyd, Heather A},
title = {Third‐Trimester Cardiovascular Function and Risk of Hypertensive Disorders of Pregnancy},
journal = {Journal of the American Heart Association},
year = {2024},
doi = {10.1161/jaha.123.032673}
}
EUVIMED